Ben Mapa1, Blake E S Taylor2, Geoffrey Appelboom3, Eliza M Bruce3, Jan Claassen4, E Sander Connolly5. 1. Cerebrovascular Lab, Columbia University Medical Center, New York, New York, USA. 2. Cerebrovascular Lab, Columbia University Medical Center, New York, New York, USA; Department of Neurosurgery, Columbia University, New York, New York, USA. Electronic address: bet2110@cumc.columbia.edu. 3. Cerebrovascular Lab, Columbia University Medical Center, New York, New York, USA; Department of Neurosurgery, Columbia University, New York, New York, USA. 4. Department of Neurology, Columbia University, New York, New York, USA; Neuro-intensive Care Unit, Columbia University, New York, New York, USA. 5. Cerebrovascular Lab, Columbia University Medical Center, New York, New York, USA; Department of Neurosurgery, Columbia University, New York, New York, USA; Department of Neurology, Columbia University, New York, New York, USA.
Abstract
BACKGROUND: Hyponatremia is a common metabolic disturbance after aneurysmal subarachnoid hemorrhage (SAH), and it may worsen outcomes. This review aims to characterize the effect of hyponatremia on morbidity and mortality after SAH. OBJECTIVES: We sought to determine the prevalence of hyponatremia after SAH, including in subgroups, as well as its effect on mortality and certain outcome measures, including degree of disability and duration of hospitalization. METHODS: A search of terms "hyponatremia" and "subarachnoid hemorrhage" was performed on PubMed, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and EMBASE. Studies were included if they reported prevalence of hyponatremia and if they discussed outcomes such as mortality, duration of stay, functional outcomes (e.g., Glasgow Outcomes Scale), or incidence of complications in patients with aneurysmal SAH. Two independent researchers assessed the titles and abstracts and reviewed articles for inclusion. RESULTS: Thirteen studies met inclusion criteria. The prevalence of at least mild hyponatremia was 859 of 2387 (36%) of patients. Hyponatremia was associated with vasospasm and duration of hospitalization, but it did not influence mortality. CONCLUSION: Hyponatremia is common after SAH, and there is evidence that it is associated with certain poorer outcomes. Larger, prospective studies are needed to assess these findings and provide further evidence.
BACKGROUND:Hyponatremia is a common metabolic disturbance after aneurysmal subarachnoid hemorrhage (SAH), and it may worsen outcomes. This review aims to characterize the effect of hyponatremia on morbidity and mortality after SAH. OBJECTIVES: We sought to determine the prevalence of hyponatremia after SAH, including in subgroups, as well as its effect on mortality and certain outcome measures, including degree of disability and duration of hospitalization. METHODS: A search of terms "hyponatremia" and "subarachnoid hemorrhage" was performed on PubMed, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and EMBASE. Studies were included if they reported prevalence of hyponatremia and if they discussed outcomes such as mortality, duration of stay, functional outcomes (e.g., Glasgow Outcomes Scale), or incidence of complications in patients with aneurysmalSAH. Two independent researchers assessed the titles and abstracts and reviewed articles for inclusion. RESULTS: Thirteen studies met inclusion criteria. The prevalence of at least mild hyponatremia was 859 of 2387 (36%) of patients. Hyponatremia was associated with vasospasm and duration of hospitalization, but it did not influence mortality. CONCLUSION:Hyponatremia is common after SAH, and there is evidence that it is associated with certain poorer outcomes. Larger, prospective studies are needed to assess these findings and provide further evidence.
Authors: E Sbardella; A M Isidori; G Arnaldi; M Arosio; C Barone; A Benso; R Berardi; G Capasso; M Caprio; F Ceccato; G Corona; S Della Casa; L De Nicola; M Faustini-Fustini; E Fiaccadori; L Gesualdo; S Gori; A Lania; G Mantovani; P Menè; G Parenti; C Pinto; R Pivonello; P Razzore; G Regolisti; C Scaroni; F Trepiccione; A Lenzi; A Peri Journal: J Endocrinol Invest Date: 2017-11-20 Impact factor: 4.256
Authors: Mendel Castle-Kirszbaum; Mervyn Kyi; Christopher Wright; Tony Goldschlager; R Andrew Danks; W Geoffrey Parkin Journal: Neurosurg Rev Date: 2021-01-03 Impact factor: 3.042
Authors: Melissa M J Chua; Alejandro Enríquez-Marulanda; Santiago Gomez-Paz; Yosuke Akamatsu; Mohamed M Salem; Georgios A Maragkos; Luis C Ascanio; Khalid A Hanafy; Corey R Fehnel; Christopher S Ogilvy; Justin Moore; Ajith J Thomas Journal: J Stroke Cerebrovasc Dis Date: 2021-11-05 Impact factor: 2.136
Authors: Akshitkumar M Mistry; Jordan A Magarik; Michael J Feldman; Li Wang; Christopher J Lindsell; Matthew R Fusco; Rohan V Chitale; Gordon R Bernard; Wesley H Self; Todd W Rice; Christopher G Hughes; Eva A Mistry; Matthew W Semler Journal: Stroke Vasc Interv Neurol Date: 2022-05-08
Authors: Jeremy Cohen; Anthony Delaney; James Anstey; Matthew Anstey; Deborah Barge; Rinaldo Bellomo; Vishnu Bhardwa; Gail Brinkerhoff; Jasmin Board; Anna Campain; D James Cooper; Gian Luca Di Tanna; Mark Finnis; Emily Fitzgerald; Oliver Flower; Paul Healey; Anna Hunt; Cassie Lawrence; Jan Merthens; Lynette Newby; David Pearson; Eamon Raith; Yvonne Robertson; Sacha Schweikert; Therese Starr; Mandy Tallott; Andrew van der Poll; Paul Young; Andrew Udy Journal: Crit Care Explor Date: 2021-06-08